<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949154</url>
  </required_header>
  <id_info>
    <org_study_id>201600693</org_study_id>
    <nct_id>NCT02949154</nct_id>
  </id_info>
  <brief_title>Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients</brief_title>
  <official_title>Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective study investigating the relationship between FDG-PET uptake and LDH levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient characteristics, tumour characteristics including the BRAF mutation status and
      baseline serum S100B and LDH levels of each patient will be retrospectively determined from
      the electronical patient file. In each patient, tumour burden and 18F-FDG uptake of the
      tumour lesions will be measured using multiple standard quantification parameters of the
      baseline 18F-FDG-PET scan. Tumour burden will also be measured on the baseline contrast
      enhanced CT scan. The correlation of each FDG-PET parameter with baseline LDH and S100B
      levels, respectively, will be analyzed using univariate and multivariate regression analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Independent correlation between baseline serum LDH level and 18F-FDG uptake of tumour lesions</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between baseline serum LDH level and tumour 18F-FDG uptake in subgroups separated by metastasis site</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between baseline serum S100B level and tumour 18F-FDG uptake</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between tumour burden as measured on CT scan and on 18F-FDG-PET</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between tumour volume as determined by manual measurement or semiautomatic measurement</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of baseline serum LDH level with tumour volume as measured on CT scan and as measured on 18F-FDG-PET scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Metastatic melanoma patients</arm_group_label>
    <description>All patients &gt;18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic melanoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All patients &gt;18 years with histologically proven metastatic melanoma (American Joint
        Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and
        December 2015.

        Exclusion Criteria:

          -  participation in interventional studies

          -  missing baseline 18F-FDG PET scan and/or baseline contrast enhanced CT scan

          -  missing baseline serum LDH level

          -  missing BRAF mutation status, concurrent malignancies or a history of previous
             malignancies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Jalving, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Dr. M. Jalving</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

